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Background: To investigate prognosis and effects of ﬁrst-line therapy in elderly primary central nervous system
lymphoma (PCNSL) patients.
Patients and methods: A systematic review of studies about ﬁrst-line therapy in immunocompetent patients ≥60
years with PCNSL until 2014 and a meta-analysis of individual patient data from eligible studies and international colla-
borators were carried out.
Results: We identiﬁed 20 eligible studies; from 13 studies, we obtained individual data of 405 patients, which were
pooled with data of 378 additional patients (N = 783). Median age and Karnofsky Performance Score (KPS) was 68 years
(range: 60–90 years) and 60% (range: 10%–100%), respectively. Treatments varied greatly, 573 (73%) patients received
high-dose methotrexate (HD-MTX)-based therapy. A total of 276 patients received whole-brain radiotherapy (median 36
Gy, range 28.5–70 Gy). KPS≥ 70% was the strongest prognostic factor for mortality [hazard ratio (HR) 0.50, 95% conﬁ-
dence interval (CI) 0.41–0.62]. After a median follow-up of 40 months, HD-MTX-based therapy was associated with
improved survival (HR 0.70, 95% CI 0.53–0.93). There was no difference between HD-MTX plus oral chemotherapy and
more aggressive HD-MTX-based therapies (HR 1.39, 95% CI 0.90–2.15). Radiotherapy was associated with an improved
survival, but correlated with an increased risk for neurological side-effects (odds ratio 5.23, 95% CI 2.33–11.74).
Conclusions: Elderly PCNSL patients beneﬁt from HD-MTX-based therapy, especially if combined with oral alkylating
agents. More aggressive HD-MTX protocols do not seem to improve outcome. WBRT may improve outcome, but is
associated with increased risk for neurological side-effects. Prospective trials for elderly PCNSL patients are warranted.
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introduction
Primary central nervous system lymphoma (PCNSL) is an aggres-
sive non-Hodgkin lymphoma (NHL) mostly of B-cell origin, which
exclusively invades the central nervous system compartment. It
accounts for 3%–4% of all primary brain tumors and 4%–6% of
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extranodal lymphomas [1]. The incidence of PCNSL in immuno-
competent patients has been steadily increasing over the last
30 years [2, 3]. High-dose methotrexate (HD-MTX) in combin-
ation with HD-cytarabine (HD-AraC) is the backbone of current
treatment [4]. A recent randomized, controlled trial investigated
the role of whole-brain radiotherapy (WBRT) as consolidation
compared with no consolidation therapy, suggesting that WBRT
does not prolong survival but enhances disease control [5].
However, despite treatment improvement, the prognosis of
PCNSL patients is still poor compared with systemic NHL [6].
Patients older than 60 years account for 50% of all PCNSL
cases. Although elderly patients are able to tolerate aggressive
systemic chemotherapy [7], they have an inferior prognosis
compared with younger patients and are more seriously affected
by iatrogenic toxicity, especially neurological side-effects follow-
ing WBRT [8]; therefore, they represent a unique and vulnerable
treatment subgroup [9, 10]. An US registry study of 579 elderly
patients diagnosed with PCNSL in the 1990s revealed that the
median survival was only 7 months and WBRT alone was the
most common treatment modality (46%) [11]. To date, a sys-
tematic summary of the research efforts to optimize therapy for
elderly PCNSL patients is missing. Therefore, we conducted a
systematic review and individual patient data meta-analysis to
comprehensively investigate prognosis and treatment strategies
for elderly patients with newly diagnosed PCNSL.
patients andmethods
systematic review of the literature
We included any study that focused on ﬁrst-line therapy and
outcome in exclusively immunocompetent PCNSL patients ≥60
years. We searched Medline, EMBASE, and the Cochrane
Library from database initiation until November 2014. We also
searched annual meeting abstracts of the following societies
(2010–2014): European hematology association (EHA),
American Society of Clinical Oncology (ASCO), and American
Society of Hematology (ASH). Two investigators (VG and BK)
independently reviewed potentially eligible titles, abstracts and
full texts if eligible. We asked all primary investigators of eligible
studies to provide individual patient data.
individual patient data meta-analysis
Individual patient data from the identiﬁed studies were pooled
with published and unpublished data of elderly PCNSL patients
from international collaborators to maximize generalizability
and statistical power. Anonymized patient data were collected
using a prespeciﬁed case report form. The Research Ethics
Committee of the University of Basel approved this study.
end point deﬁnitions
Main end points of our individual patient data meta-analysis
were: (i) overall survival (OS, deﬁned as time from diagnosis
until death due to any cause or date of last follow-up visit) and
(ii) progression-free survival (PFS, deﬁned as time from diagno-
sis until progression, relapse, or death; whichever occurred ﬁrst,
or date of last follow-up visit). Further end points included:
complete remission (CR), partial remission (PR), stable disease
(SD), and progressive disease (PD). We considered the response
status as reported in the publications or as provided by
the cooperating investigators. Clinical apparent neurological
side-effects were deﬁned as any signiﬁcant and progressive
neurological deterioration in the absence of disease progression
developing at any time after start of treatment.
investigated treatments
Patients were categorized as follows: (i) HD-MTX-based therap-
ies [deﬁned as any therapy that contained HD-MTX (>1 g/m2)]
versus no HD-MTX (including those only receiving WBRT);
(ii) HD-MTX monotherapy versus HD-MTX plus any other
chemotherapy, (iii) HD-MTX in combination with oral chemo-
therapy only versus HD-MTX plus at least two other i.v. agents
(aggressive) (steroids were not considered as a single agent); and
(iv) HD-MTX-based therapy with WBRT versus HD-MTX-
based therapy without WBRT. We restricted our investigations
to these four categories to address basic therapeutic principles
and to preserve sufﬁcient numbers of patients and events. We
did not investigate the association between rituximab and the
respective outcomes, because the follow-up times in patients re-
ceiving rituximab was much shorter compared with those not
receiving it, preventing reliable conclusion.
statistical analysis
We used multivariable Cox regression analysis with a random
effect for study/database for all prognostic analyses, which were
conducted on the complete dataset. In sensitivity analyses, we
restricted our analysis to patients being diagnosed after 1997 or to
prospective studies. For exploratory purposes, we additionally ana-
lyzed survival within different time periods of diagnosis (periods
of 10 years). Follow-up was estimated using the inverse Kaplan–
Meier method [12]. We used Kaplan–Meier plots, logistic, and
Cox regression models to compare the different treatment regi-
mens with respect to response rate, PFS, and OS. Each analysis was
adjusted for age, KPS (≥70% versus <70%), and a random effect
for study/database was added. The impact of WBRT on OS and
PFS was not investigated using the Cox regression model, because
of severe violation of the proportional hazards assumption. For all
treatment regimens, we additionally investigated whether the asso-
ciation between treatment and outcome differed by KPS status and
tested possible interactions. The impact of WBRT on neurological
side-effects was investigated using random-effect logistic regression
adjusted for the factors mentioned above. P < 0.05 (two-sided) was
considered signiﬁcant. Further details about methods and statistic-
al analyses are provided in the supplementary Material S1, avail-
able at Annals of Oncology online.
results
studies identiﬁed by the systematic review
We identiﬁed 20 eligible studies published between 1996 and
2014 including 1103 patients (supplementary Figure S2, available
at Annals of Oncology online) [13–32]. Detailed characteristics
of identiﬁed studies, applied therapies, and outcomes are sum-
marized in Table 1. In 13/20 (65%) studies, patient data were
collected from more than one center [13, 15–18, 21, 23, 25–27,
29–31]; of those, 8 (62%) were planned prospectively [15, 16, 18,
25–27, 30, 31]. The assessment of the methodological quality of
 | Kasenda et al. Volume 26 | No. 7 | July 2015
reviews Annals of Oncology
studies is provided in supplementary Material S3, available at
Annals of Oncology online. Only three studies (15%) reported
neurocognitive outcomes as measured with the mini-mental-
state examination tool [13, 30, 33]. Patient recruitment for the
only identiﬁed randomized trial (N = 98) has recently been com-
pleted and preliminary data were presented in abstract form
[25]. This phase II trial suggests that HD-MTX plus procarba-
zine and vincristine followed by cytarabine (MPV-A) may be
more effective compared with HD-MTX plus temozolomide
regarding response, PFS, and OS (Table 1) with similar toxicities
(≥grade 3 toxicities 72% versus 71%); however, the differences
were not statistically signiﬁcant. The investigators also evaluated
neurocognitive outcomes and quality of life, but they were not
reported in the abstract [25]. The publication by Roth et al.
reported data of the subgroup of elderly PCNSL patients (≥70
years) who were enrolled in the randomized G-PCNSL-SG-1
trial, which was not speciﬁcally designed for elderly patients
[26]. One German multicenter single-arm study including
patients ≥65 years of age recently completed recruitment of 112
patients, but no data have yet been published (NCT00989352).
individual patient data meta-analysis
patient characteristics. From the identiﬁed 20 studies, 405
(40%) individual patient data [13, 14, 17–21, 23, 24, 30, 33, 34]
were available for our individual patient data meta-analysis and
pooled with 378 published and unpublished patient data from 6
other databases (Milan N = 9 [35], N = 18 [36], N = 183 [37],
N = 36 [4]; Boston N = 22 [not published]; Freiburg, N = 67 [not
published]; Tel Aviv, N = 16 [not published]; Rochester N = 27
[not published]). Altogether 783 patients diagnosed from 1977
to 2014 were included in our individual patient data meta-analysis
(supplementary Figure S2, available at Annals of Oncology online).
Two hundred sixty-one of 783 (33%) patient data were collected
in prospective studies, 67% were collected in retrospective
studies. Patients’ characteristics are summarized in Table 2.
Applied treatment regimens varied widely and are listed in
detail in the supplementary Material S4, available at Annals of
Oncology online) (only patients included in the individual
patient data meta-analysis). Overall, WBRT monotherapy was
the most common treatment modality (13%), followed by HD-
MTX monotherapy (9%). Patients being diagnosed after 1997
(N = 552) were mostly treated with HD-MTX monotherapy
(10%), second most frequent treatment was HD-MTX plus oral
chemotherapy (9%).
prognostic factors
After a median follow-up of 40 months [95% conﬁdence inter-
val (CI) 36.0–47.0], 507 (65%) patients died. Median PFS and
OS were 10 (95% CI 8.0–12.0) and 19 months (95% CI 16.0–
21.0), respectively (Figure 1A). Grouping patients by time of
diagnosis revealed improvement over time regarding OS;
patients younger than 65 years seemed to have the best survival
prognosis (Figure 1B and C). Table 3 summarizes the results
from the multivariable analyses for OS. A KPS ≥70% was sig-
niﬁcantly associated with improved survival. Other factors such
as involvement of deep brain structures, cerebrospinal ﬂuid
protein elevation, and serum lactate dehydrogenase had no
impact on OS or PFS (supplementary Material S5, available at
Annals of Oncology online). Our sensitivity analyses conditional
on time of diagnosis (diagnosed after 1997) and study design
also supported the strong prognostic value of KPS (data not
shown).
cause of death
Of those 508 (65%) patients who died, causes of death were
PCNSL in 310 (61%), treatment-related complications in 34
(7%), sepsis in 25 (5%) of patients. Twenty-one patients (4%)
died of other causes. Cause of death was unknown in 118 (23%)
deceased patients.
response to treatment
Overall 531 of 783 (68%) patients responded to ﬁrst-line treat-
ment [375 (48%) CR, 156 (20%) PR, 19 (2%) SD, 130 (19%) PD,
and in 81 (10%) response status was missing]. Altogether, 466
of 783 (60%) patients experienced either progression or relapse.
Any HD-MTX-based therapy was associated with better res-
ponse compared with therapies not containing HD-MTX (73%
versus 55%), but the difference was not statistically signiﬁcant in
the adjusted analysis. High-dose MTX plus any other chemo-
therapy was signiﬁcantly associated with higher response rates
compared with HD-MTX monotherapy (73% versus 68%) in
the adjusted analysis. Overall response rates between HD-MTX
combined with oral chemotherapy and HD-MTX plus at least
two other i.v. agents (aggressive) were similar (73% versus 75%).
Further details are given in supplementary Material S6, available
at Annals of Oncology online.
treatment regimens and survival
Of 573 patients (73%) who received any HD-MTX-based chemo-
therapy for ﬁrst-line therapy, the median number of applications
was 4 (range, 1–29) with a median HD-MTX dosage of 3 g/m2
(range, 1–8 g/m2), 396/573 (77%) patients received ≥3 g/m2.
Any HD-MTX-based therapy (N = 573, HD-MTX ≥1 g/m2)
was independently associated with improved OS compared with
therapies without HD-MTX (N = 210), which also included
WBRT monotherapy (Table 4) [unadjusted 12- and 24-month
OS rates: 63% (95% CI 59% to 67%) versus 47% (95% CI 40% to
53%) and 49% (95% CI 44% to 53%) versus 29% (95% CI 23%
to 36%), respectively—Figure 2A]. This association was consist-
ent throughout KPS subgroups and in the subpopulation of
patients not receiving any WBRT during ﬁrst-line treatment.
Sensitivity analysis based on patients being diagnosed after 1997
revealed similar results. There was also a positive association
regarding PFS without statistical signiﬁcance (adjusted HR 0.80,
95% CI 0.61–1.04, P = 0.100). In the unadjusted analysis,
patients treated with HD-MTX plus any other chemotherapy
[median HD-MTX applications 4, interquartile range (IQR) 2–
5] only tended to have an improved prognosis compared with
HD-MTX monotherapy (median HD-MTX applications 3, IQR
1–7) (Figure 2B) [unadjusted 12- and 24-month OS rates: 64%
(95% CI 0.60% to 0.68%) versus 57% (95% CI 0.44% to 0.67%)
and 50% (96% CI 0.45% to 0.55%) versus 41% (95% CI 0.29% to
0.53%)]. However, the association was statistically signiﬁcant in
the adjusted multivariable analysis (Table 4) and also in our sen-
sitivity analyses restricted to patients being diagnosed after 1997
(adjusted HR 0.63, 95% CI 0.45–0.89) or treated within
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Table 1. Characteristics of included studies
References In
IPDMA
No. of
patients
Median
age
Design HD-
MTX
CTX components Response
evaluation
Response rate
(CR rate) %
Median FU
(months)
Median PFS
(months)
Median OS
(months)
Freilich et al. [13] Yes 12 76 Retro multi Yes 1. HD-MTX, IT-MTX, PCB,
VINCR; 2. HD-MTX, IT-MTX,
AraC; 3.HD-MTX, PCB, IT-
MTX, TT
CT or MRI 91 (75) 13 n.r. 31
Fritsch et al. [24] Yes 28 75 Pros single Yes R, HD-MTX, CCNU, PCB MRI 82 (64) 36 16 18
Ghesquieres et al. [18], Ab Yes 36 66 Pros multi Yes COP, MCOPA, low-dose CYM. CT or MRI 61 (53) n.r. 16 16
Ghesquieres et al. [18], Bb Yes 18 73 Pros multi Yes MCVP CT or MRI 56 (28) n.r. 7 15
Hoang-Xuan et al. [33] Yes 50 72 Pros multi Yes HD-MTX, CCNU, PCB, IT-
MTX, steroids
CT or MRI 48 (42) 36 7 14
Illerhaus et al. [19] Yes 30 70 Pros single Yes HD-MTX, CCNU, PCB MRI 70 (44) 78 6 15
Kurzwelly et al. [21] Yes 17 75 Retro multi No TMZ MRI 53 (47) 25 5 21
Laack et al. [16] No 19 76 Pros multi No WBRT, steroids MRI 42 (16) 6 3 6
Lee et al. [29]$c Yes 38 69 Retro single Yes HD-MTX, RANIMST, PCB,
steroids
MRI 74 (42) 36.5 18 43
Makino et al. [32] No 63 n.r. Retro single Yes HD-MTX, RANIMST, PCB,
steroids
MRI n.r. n.r. 7 31
Ney et al. [22] No 174 72 Retro single Yes HD-MTX, WBRT CT or MRI 76 (n.r.) 34 24 25
Ng et al. [14] Yes 10 73 Retro unclear Yes HD-MTX n.r. 90 (60) 23 18 36
Olivier et al. [31] No 35 65 Pros multi Yes HD-MTX, VIND, IDA, steroids MRI 51 (17) 57 13 19
Omuro et al. [17] Yes 23 68 Retro multi Yes HD-MTX, TMZ n.r. 70 (55) 26 8 35
Omuro et al. [25]a No 98 72 RCT multi Yes MPV-A versus HD-MTX TMZ n.r. 82 (62) versus
71 (45)
n.r. 9.5 versus
6.1
31 versus
13.8
Pulczynski et al. [30]d Yes 42 66 Pros multi Yes HD-MTX, ARAC, TMZ MRI 88 (60) 24 13 Not reached
Roth et al. [26] No 192 n.r. RCT multi Yes HD-MTX (IFO) CT or MRI 44 (30) n.r. 4 13
Schlegel et al. [27]a No 89 68 Pros multi Yes HD-MTX, ARAC, DEXA, IF,
CYLCO, VINCR, IT-ARAC
n.r. 57 (49) 12 8 22
Schuurmans et al. [23] Yes 74 65 Retro multi Yes 1. WBRT only; 2. HD-HD-MTX;
3. MBVP
n.r. 74 (n.r.) 20 7 21
Welch et al. [28] No 24 82 Retro single Yes MVP CT or MRI 63 (58) 15 7 8
Zhu et al. [20] Yes 31 74 Retro single Yes HD-MTX MRI 96 (60) 28 7 37
aOnly published in abstract form.
bResults from one single study that stratified therapy according to age (A, 61–69 years; B, ≥70 years).
$cThis is an updated study of previously reported patients by Taoka et al. [34].
dStudy also included patients below 60 years of age, in total N = 66.
ARAC, cytarabine; CCNU, lomustine; CR, complete remission; CT, computed tomography; CTX, chemotherapy; FU, follow-up; HD-MTX, high-dose methotrexate; IDA, idarubicine; IFO, ifosfamide; IT,
intrathecal; IPDMA, individual patient data meta-analysis; multi, multicenter study; MBVP, MTX–BCNU–teniposide–dexamethason; MVP, high-dose methotrexate–vincristine–procarbazine; MRI, magnetic
resonance imaging; n.r., not reported; PBC, procarbazine; PR, partial remission; RANIMST, ranimustine; single, single-center study; pros, prospective study; retro, retrospective study; R, rituximab; RCT,
randomized clinical trial; TMZ, temozolomide; TT, thiotepa; VINCR, vincristine; VIND, vindesin; WBRT, whole-brain radiotherapy.
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prospective studies (adjusted HR 0.39, 95% CI 0.21–0.71).
Furthermore, HD-MTX plus other chemotherapy was signiﬁ-
cantly associated with improved PFS (adjusted HR 0.39, 95% CI
0.27–0.58, P < 0.001).
Therapies combining HD-MTX plus at least two other i.v.
agents (aggressive, median HD-MTX applications 3, IQR 2–4)
were not associated with improved OS compared with HD-
MTX plus oral chemotherapy only (e.g. HD-MTX combined
with temozolomide or procarbazine, median HD-MTX applica-
tions 6, IQR 3–8) (Table 4) [unadjusted 12- and 24-month OS
rates: 65% (95% CI 56% to 72%) versus 65% (95% CI 57% to
71%) and 50% (95% CI 51% to 58%) versus 50% (95% CI 42%
to 58%)] (Figure 2C). In patients with a KPS ≥70% HD-MTX
plus oral chemotherapy showed a trend for better OS [unadjust-
ed 12- and 24-month OS rates: 78% (95% CI 66% to 86%)
versus 73% (95% CI 64% to 83%) and 66% (95% CI 53% to 77%)
versus 56% (95% CI 44% to 66%); log-rank test P = 0.0926], but
the tested interaction was not signiﬁcant. The sensitivity analyses
restricted to patients being diagnosed after 1997 or treated in pro-
spective studies revealed similar results. There was no difference
regarding PFS (adjusted HR 1.26, 95% CI 0.80–1.99).
Overall, the addition of WBRT in those patients being treated
with any HD-MTX-based chemotherapy (with WBRT, median
HD-MTX applications 4, IQR 2–6; without WBRT, median
HD-MTX applications 4, IQR 2–4) was associated with an OS
beneﬁt (Figure 2D) [unadjusted 12- and 24-month OS rates:
78% (95% CI 70% to 85%) versus 59% (95% CI 54% to 63%)
and 59% (95% CI 50% to 68%) versus 46% (95% CI 41% to 51%);
Table 2. Patient’s characteristics
Baseline
characteristics
IPD not from
review
(N = 378)
IPD from
review
(N = 405)
All
(N = 783)
Sex
Female 174 (46) 218 (53.8) 392 (50.1)
Age at diagnosis
Median (IQR) 67 (63, 72) 70 (65, 74) 68 (64, 73)
<65 151 (40) 105 (26) 256 (33)
65–70 118 (31) 115 (28) 233 (30)
71–75 72 (19) 109 (27) 181 (23)
>75 37 (10) 76 (19) 113 (14)
KPS
Median % (IQR) 60 (40, 80) 60 (50, 80) 60 (50, 80)
KPS≥ 70% 150 (40) 182 (45) 332 (42)
KPS < 70% 178 (47) 193 (48) 371 (47)
Missing values 50 (13) 30 (7) 80 (10)
Serum LDH at diagnosis
Elevated 98 (26) 70 (17) 168 (21)
Normal 158 (42) 92 (23) 250 (32)
Missing values 122 (32) 243 (60) 365 (47)
Involvement of deep brain structures
Yes 193 (51) 152 (38) 345 (44)
No 144 (38) 110 (27) 254 (32)
Missing values 41 (11) 143 (35) 184 (24)
Elevated CSF protein
Yes 106 (28) 63 (16) 169 (22)
No 83 (22) 29 (7) 112 (14)
Missing values 189 (50) 313 (77) 502 (64)
Year of diagnosis
1977–1986 31 (8) 0 31 (4)
1987–1996 151 (40) 30 (7) 181 (23)
1997–2007 116 (31) 262 (65) 378 (48)
After 2007 78 (21) 96 (24) 174 (22)
Missing values 2 (1) 17 (4) 19 (2)
Values are frequencies (percentages) unless otherwise specified.
CSF, cerebrospinal fluid; IPD, individual patient data; IQR, interquartile
range; KPS, Karnofsky performance score; LDH, serum lactate
dehydrogenase.
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Figure 1. (A) Overall and progression-free survival of the whole cohort; (B)
overall survival grouped by time of diagnosis (in 19 cases, exact date was
missing); (C) overall survival grouped by age groups.
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log-rank test P = 0.0010]. This association was not consistent
throughout the KPS subgroups; patients with a KPS≥ 70% did
not seem to beneﬁt [unadjusted 12 and 24-months OS rates: 81%
(95% CI 69% to 88%) versus 71% (95% CI 64% to 77%) and 65%
(95% CI 52% to 75%) versus 59% (95% CI 52% to 67%); log-rank
test P = 0.6239]. Regarding PFS, addition of WBRT showed a
positive association overall and throughout KPS subgroups in
patients who were treated with HD-MTX-based chemotherapy.
When we considered ≥3 g/m2 as the cutoff to deﬁne HD-
MTX therapy, results were very similar and did not change our
conclusions compared with the cutoff at 1 g/m2. Protocols based
on HD-MTX ≥3 g/m2 were not signiﬁcantly associated with
better OS compared with HD-MTX protocols with <3 g/m2
(log-rank test P = 0.116). Further details are provided in supple-
mentary Figure S7, available at Annals of Oncology online.
WBRT and neurological side-effects
Two hundred seventy-six of 783 (35%) patients received WBRT
as part of ﬁrst-line therapy (median 36 Gy, range 28.5–70 Gy);
140 of 276 (51%) received a dose of more than 36 Gy. In total, 65
of 783 (8.3%) patients were reported to have clinical apparent
neurological side-effects. In 91 cases (12.3%), no explicit informa-
tion about neurological side-effects was available. The remaining
627 patients (80.1%) were reported as being free of neurological
side-effects. Whole-brain radiotherapy was independently asso-
ciated with an increased risk for neurological side-effects
(adjusted odds ratio 5.23, 95% CI 2.33–11.74, P < 0.001). Of those
136 patients who were treated with <36 Gy, 38 (28%) developed
neurological side-effects (missing information about neurological
side-effects, 24%), whereas of those patients being treated with
more than 36 Gy, 14% developed neurotoxicity (missing informa-
tion about neurological side-effects, 12%).
salvage therapies
Of 466 patients (60%) with progressive or relapsing disease, 209
(45%) received salvage therapy [40 HD-MTX-based chemother-
apy (19%), 83 (40%) non-HD-MTX-based chemotherapy, 62
(30%) only WBRT, in 24 (12%) cases information about salvage
therapy was not available]. Further details of salvage therapies
stratiﬁed by ﬁrst-line treatment and time are provided in supple-
mentary Material S8, available at Annals of Oncology online.
discussion
To our knowledge, this is the largest systematic review and indi-
vidual patient data meta-analysis of the therapeutic management
and outcome of elderly patients with PCNSL. Results revealed an
improvement of prognosis over the last decade. Among a wide
variety of treatment approaches for elderly patients with newly
diagnosed PCNSL, HD-MTX-based therapies were associated
with signiﬁcantly better results. High-dose MTX in combination
with at least two other i.v. drugs (aggressive) compared with HD-
MTX plus oral chemotherapy were not associated with improved
response or survival. In those patients that received HD-MTX-
based chemotherapy, WBRT was associated with improved PFS,
OS, but also with an increased risk of neurological side-effects.
Given the lack of standardized neurological testing and poor
reporting of this outcome, deﬁnite conclusions about the magni-
tude of this association are difﬁcult to draw.
Although large in scale, our study has limitations. First,
the predominant retrospective nature of the dataset implies
inconsistent data quality throughout the different data sources.
For example, information about different baseline characteristics
crucial for calculation of the “International Extranodal Lymphoma
Study Group (IELSG)” score was missing. Consequently, only a
restricted number of patients were included in the multivariable
analysis to test the prognostic discrimination of components of the
Table 3. Analysis of prognostic factors for mortality (based on 692
complete cases)
Factor Hazard ratio 95% CI P value
Age
<65 Reference n.a. n.a.
65–70 1.13 0.88–1.44 0.336
71–75 1.16 0.89–1.52 0.277
>75 1.36 0.98–1.89 0.067
KPS≥ 70% 0.50 0.41–0.62 <0.001
CI, confidence interval; KPS, Karnofsky performance score.
Table 4. Multivariable Cox regression analyses for mortality in
selected therapies
Factors HR 95% CI P value
HD-MTX versus no-HD-MTX 0.70 0.53–0.93 0.013
Age
<65 Reference n.a. n.a.
65–70 1.12 0.88–1.43 0.367
71–75 1.16 0.89–1.51 0.286
>75 1.30 0.94–1.81 0.113
KPS≥ 70% 0.51 0.41–0.62 <0.001
HD-MTX + any other CT versus
HD-MTX monotherapy
0.54 0.35–0.84 0.006
Age
<65 Reference
65–70 0.91 0.66–1.21 0.502
71–75 0.85 0.62–1.18 0.328
>75 1.08 0.72–1.59 0.711
KPS≥ 70% 0.49 0.38–0.62 <0.001
HD-MTX +multiagent i.v. CTa
versus HD-MTX + oral CT
1.39 0.90–2.15 0.143
Age
<65 Reference
65–70 1.11 0.76–1.64 0.584
71–75 1.23 0.77–1.95 0.389
>75 1.79 1.09–2.93 0.022
KPS≥ 70% 0.48 0.35–0.66 <0.001
aHD-MTX plus at least two other i.v. agents (aggressive).
CI, confidence interval; CT, chemotherapy; HD-MTX, high-dose
methotrexate; HR, hazard ratio; KPS, Karnofsky performance score;
WBRT, whole-brain radiotherapy.
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IELSG score; thus, these results should be cautiously interpreted.
The issue of missing data does not only apply to baseline variables,
central pathology review, and information about co-morbidities,
but also to acute toxicities during, reasons for treatment termin-
ation, and causes of death. In addition, we were not able to include
all patients from eligible studies in our individual patient data
meta-analysis and had to restrict our investigations of the associa-
tions between different treatment regimens and outcome to a
limited number. This was necessary to preserve a sufﬁcient
number of patients and events in each chosen treatment category
to obtain reliable conclusions. However, to maximize generalizabil-
ity, we included additional patient data from other databases and
accounted for the heterogeneity of data sources in our analysis. In
particular, the prognostic analyses proved robust in our sensitivity
analysis focusing on prospective studies and year of diagnosis. The
deﬁnition of neurological side-effects was broad and not based on
formal cognitive testing, because we a priori assumed that neuro-
logical testing was standardized in the minority of studies.
Therefore, assuming that only severe forms of clinically apparent
neurological side-effects were reported, it is likely that the actual
rate of patient impairment due to neurological side-effects is higher
than reported herein. Moreover, information on other risk
factors, e.g. use of anticonvulsant drugs or pre-existing cerebral
vasculopathy, were not available and effects on neurological
status could not be addressed. Interpretation of response rates
in association with different therapies also needs to consider
the limitation of nonstandardized response criteria throughout
pooled study data.
The cutoff of 60 years was chosen, because it is the lowest
reported [7, 9]. In addition, it is also in line with other recent
trials for elderly patients suffering from systemic NHL [38]. In
univariable analysis, there was a clear association between in-
creasing age and decreased survival probability. However, if
adjusted for KPS, only some evidence remained indicating that
age above 75 is associated with a worse survival prognosis com-
pared with patients younger than 65 years of age. As reported
previously [39], KPS equal or above 70% is of high prognostic
relevance, which we could conﬁrm in our analyses. These ﬁnd-
ings indicate, that categorization only by age alone is not infor-
mative enough to make therapeutic decisions or to deﬁne trial
eligibility criteria in elderly PCNSL patients; a more appropriate
approach is to at least consider both, age and clinical perform-
ance status as already implemented in an currently ongoing
multicenter PCNSL trial (NCT01011920).
Methotrexate is now the most widely studied drug in the treat-
ment of PCNSL and its efﬁcacy has been demonstrated in several
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Figure 2. (A) Overall survival in patients receiving any HD-MTX-based therapy versus therapies not containing HD-MTX; (B) overall survival in patients re-
ceiving any HD-MTX + other chemotherapy versus HD-MTX monotherapy; (C) overall survival in patients receiving HD-MTX plus at least two other i.v.
drugs (aggressive) versus HD-MTX plus oral chemotherapy; (D) overall survival in patients receiving HD-MTX-based chemotherapy with or without whole-
brain radiotherapy. CTX, chemotherapy; HD-MTX, high-dose methotrexate; HR, hazard ratio.
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prospective trials [40–42]. Our results conﬁrm these ﬁndings also
for the subgroup of elderly PCNSL patients. However, 14% of
patients in our database were treated with WBRT only, which is
lower than previous reports based on US SEER registry data
(46%) [11]. This discrepancy may be explained by the fact that
patients included in our analyses were mostly treated at tertiary re-
ferral centers and not in the community [11]. Another explan-
ation could be that therapy and outcome of those only being
treated with WBRT were not published. Importantly, after 1997
the number of patients treated with WBRT monotherapy substan-
tially declined and HD-MTX-based therapy was the predominant
therapy of choice. A more aggressive approach consisting of HD-
MTX and at least two other i.v. agents was not associated with
improved response or OS compared with HD-MTX plus oral
chemotherapy. This may be explained by the fact that these ag-
gressive approaches also included anthracyclines and vincristine,
both are well known to be highly active in systemic NHL, but their
questionable activity in PCNSL has been reported before [43–45].
Even if some activity of these agents is assumed, the chosen com-
binations do not seem to be feasible, because patients receiving
this aggressive approach had less HD-MTX applications (median
3) compared with HD-MTX plus oral chemotherapy (median 6).
There were some discrepancies between PFS and OS estimates
in our analyses. Usually, one would rather expect signiﬁcant
effects on PFS, but not on OS, e.g. due to limited statistical power.
In our analysis, power was not an issue, but rather the fact that
patients who received HD-MTX-based chemotherapy more often
received salvage treatment, which likely improved OS. Therefore,
salvage therapy should always be considered, because it seems
that also elderly can beneﬁt from it even after an early relapse.
However, to investigate this in further detail, more clinical infor-
mation at time of relapse would have been needed.
Beside HD-MTX, there is yet no deﬁned standard treatment
of newly diagnosed PCNSL as is for instance rituximab–CHOP
for systemic NHL [40]. The only phase II randomized trial spe-
ciﬁcally designed for elderly PCNSL patients suggests that
MPV-A may be more effective compared with HD-MTX plus
temozolomide [25]; however, the differences regarding response,
PFS, or OS were not statistically signiﬁcance. Still, the MPV-A
regimen can be recommended for further development in the
treatment of elderly PCNSL patients.
A recent US multicenter single-arm study (N = 52) showed
promising results regarding long-term disease control and low
rates of neurotoxicity by using the R-MPV regimen, followed by
low-dose WBRT (23.4 Gy) and cytarabine as consolidation [46].
Another recent single-arm study (N = 42) investigated the com-
bination of rituximab, HD-MTX, and temozolomide for induc-
tion followed by consolidation with etoposide and cytarabine;
WBRT was omitted from the primary treatment strategy [47].
Both studies also showed good outcomes in the small subgroups
of patients ≥60 years of age [46, 47].
Elderly patients exhibit increased risk for neurological side-
effects when exposed to WBRT [8, 48]. In two retrospective
series, WBRT in combination with chemotherapy was not asso-
ciated with improved OS in PCNSL patients treated with HD-
MTX, but led to improved disease control [37, 49]. Similarly, in
another retrospective analysis, patients older than 60 years of
age who were treated with HD-MTX did not seem to beneﬁt
from WBRT regarding OS [50]. In all mentioned studies,
prevalence of neurological side-effects was not based on standar-
dized testing, but on a broad deﬁnition similar to ours. In con-
trast to these studies, our data suggest that WBRT may improve
OS in patients with a lower KPS. Patients with a higher KPS do
not seem to beneﬁt. Given the trade-off between a potentially
small survival beneﬁt and the risk of neurological side-effects,
which still maybe underestimated in these elderly patients, we
urge caution regarding the interpretation of WBRT being a su-
perior treatment in addition to HD-MTX this subgroup.
In conclusion, this study provides a comprehensive summary
of the available evidence for the ﬁrst-line treatment and progno-
sis of elderly PCNSL patients. HD-MTX-based therapy should
be offered to these frail patients, whenever possible. Especially,
ﬁrst-line treatment with combinations of HD-MTX with oral
alkylating agents are advisable (e.g. HD-MTX plus procarbazine
or temozolomide) and deserve to be further investigated. WBRT
may improve outcome, but is signiﬁcantly associated with increased
risk for neurological side-effects. Prospective trials designed for
elderly PCNSL patients are promptly needed.
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